[Table_Reportdate] 2025年08月26日 [证券分析师： Table_Authors] 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 ➢ 1.券商分类评价规定修订落地，关注中报配置窗口期——非银金融行业周报（20250818- 20250824） ➢ 2.开立医疗（300633）：静待招投标持续复苏，高端产品驱动未来增长——公司简评报告 ➢ 3.恒力石化（600346）：石化周期底部盈利暂时承压，"反内卷"下龙头优势有望凸显—— 公司简评报告 ➢ 4.特宝生物（688278）：业绩持续高增长，积极拓展创新技术平台——公司简评报告 ➢ 5.国产芯片新机遇，小米业绩亮眼迎新高——电子行业周报2025/8/18-2025/8/24 方霁 S0630523060001 fangji@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20250826 [tabl ...

Core Viewpoint - The company, Kexing Pharmaceutical, is actively pursuing funding to support its new drug development and international commercialization efforts, indicating a strategic focus on growth in the biopharmaceutical sector [1] Company Overview - Kexing Pharmaceutical's latest stock price is 44.63 yuan, reflecting a 0.56% increase from the previous trading day [1] - The stock reached a high of 44.91 yuan and a low of 43.26 yuan during the trading session, with a total transaction volume of 314 million yuan and a turnover rate of 3.53% [1] - The company specializes in the research, development, production, and sales of recombinant protein drugs and microbiome preparations, with key products including recombinant human erythropoietin, recombinant human interferon α1b, and Clostridium butyricum dual live bacteria [1] Financial Activities - The company plans to apply for the registration of technology innovation bonds not exceeding 800 million yuan to support new drug research and overseas commercialization [1] - The board has approved a resolution to provide interest-free loans of up to 20 million yuan to its wholly-owned subsidiary, specifically for the upgrade of the research and development center [1] Capital Flow - On the day of reporting, the net outflow of main funds was 6.722 million yuan, with a cumulative net outflow of 78.8172 million yuan over the past five trading days [1]